DETAILED ACTION
This action is in response to papers filed on 05/26/2026. Claims 1-9, and 16-22 of Song et al., 17906745 (09/19/2022) are pending examination on the merits: claims 10-15 are canceled. Claims 1-2, 4-7, and 9 are rejected and claims 3 and 8 are objected to.
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Information Disclosure Statement
The Information Disclosure Statements (IDS) submitted on 09/19/2022, 02/14/2023, 07/14/2023, 04/01/2024, and 06/07/2024 are in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statements have been considered by the examiner.
Priority
This application is a 371 of PCT/KR2021/004904 04/19/2021 which claims benefit of 63/011,351 filed on 04/17/2020.
Election/Restriction
In a response filed on 05/26/2026, Applicant elected the following group and species:
PNG
media_image1.png
152
852
media_image1.png
Greyscale
Group I, claims 1-9, drawn to compounds of formula (I) and a pharmaceutical composition comprising compounds of formula (I).
Group II, claims 16-22, drawn to methods of treatment by administering a compound of formula (I) are hereby withdrawn.
The elected species was searched and found not to be anticipated by or obvious over the prior art. The search and examination have therefore been extended to the full scope of generic claim 1. The Election of Species Requirement is therefore withdrawn.
Claim objections
Claim 8 is objected to because of the following informalities: claim 8 includes periods after the numbers in the list of compounds recited therein. Each claim begins with a capital letter and ends with a period. Periods may not be used elsewhere in the claims except for abbreviations. See Fressola v. Manbeck, 36 USPQ2d 1211 (D.D.C. 1995); See also MPEP § 608.01(m). Appropriate correction is required.
Claim Rejections - 35 USC § 102
The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention.
Claims 1-2, 4-7, and 9 are rejected under 35 U.S.C. 102 as being anticipated by Planken et al., US PG-PUB 2019/0233440 A1 (PFIZER INC.) 01 August 2019 (“Planken”).
Regarding claims 1-2, 4-7, and 9, Planken teaches the following compound:
PNG
media_image2.png
206
274
media_image2.png
Greyscale
Planken teaches compound 14 which is identical to the compound of formula (I) of claims 1, 2, 4-7, and 9, for example, in the present invention, when Ar1, Ar2=halo(CI); L=absent; and R1=H (see page 89, right column).
Allowable Subject Matter
Claims 3 and 8 are objected to as being dependent upon a rejected base claim but would be allowable if rewritten in independent form including all the limitations of the base claim and any intervening claims and if claim 8 is amended to remove extraneous periods contained in the claims as described above.
The following is a statement of reasons for the indication of allowable subject matter:
The closest prior art is US Patent No. 7,361,662 B2 (published in 2008) by Rault et al. (“Rault”).
Regarding claim 3, Ar1 and Ar2 are defined as: wherein the Arl and the Ar2 is each independently phenyl, monocyclic C5-6 heteroaryl comprising one or two hetero atoms selected from the group consisting of N, O and S, or monocyclic C5-6 heterocycloalkyl comprising one or two hetero atoms selected from the group consisting of N, O and S, which is unsubstituted or substituted with halo, hydroxyl, amino, C1-3 alkyl or C1-3 alkoxy, where C1-3 alkyl or C1-3 alkoxy is unsubstituted or substituted with one to three halo.
Rault teaches for example the following compounds (c.f., page 35 of STN search report):
PNG
media_image3.png
712
784
media_image3.png
Greyscale
The difference between the claimed invention and Rault’s compounds is the substitution between the two nitrogen which is not present in the claimed invention, and there is no motivation to modify this substitution.
Conclusion
Claims 1-2, 4-7, and 9 are rejected and claims 3 and 8 are objected to.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to CHANTAL ADLAM whose telephone number is (571)270-0923. The examiner can normally be reached Monday - Friday 8:00 am - 5:00 pm.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, JAMES HENRY ALSTRUM-ACEVEDO can be reached at (571) 272-5548. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/C A/Examiner, Art Unit 1622
August 26, 2026
/JAMES H ALSTRUM-ACEVEDO/Supervisory Patent Examiner, Art Unit 1622
Prosecution Insights